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Similar cellular responses after treatment with either 
praziquantel or oxamniquine in Schistosoma mansoni 
infection.
Abstract
The effect of  treatment with either oxamniquine or 
praziquantel on S.mansoni specific IFN-gamma, IL-4 , IL-5 
and IL-10 was compared on PBMC which were collected pre-
treatment, 6 and 18 weeks post treatment. Using sandwich 
ELISA on the supernatants harvested from the PBMC 
stimulation by crude S. mansoni SEA and SWAP antigens 
after 5 days the levels of  PBMC proliferation and cytokine 
production were similar according to treatment with either 
praziquantel or oxamniquine. Before treatment, infected 
groups showed low ratios, of  IL-4:IFN-gamma, IL-5:IFN-
gamma and IL-10:IFN-gamma, indicating that IFN-gamma 
was high in the infected individuals. The general increase 
in immuno-modulation was observed post-treatment with 
elevated immune reactivity and cytokine production in both 
treatment groups. Treatment induced significant increases in 
levels of  IL-4 (p<0.05), IL-5 (p<0.0001) and IL-10 (p<0.05) 
cytokines 6 and 18 weeks after treatment. There were no 
significant differences in the increase in IL-4, IL-5 and IL-10 
between children treated with praziquantel or oxamniquine. 
Pre-treatment IFN-gamma and IL-5 levels were positively 
correlated with infection (p<0.001), while post treatment 
IL-4 cytokine levels were negatively correlated with baseline 
infection status (p<0.001). The results suggest that treatment-
induced immune responses are similar for both commonanti-
schistosome drugs praziquantel or oxamniquine having 
similar and immunizing effect.
Introduction
Schistosome infections under various field and experimental 
settings have suggested that hosts develop some acquired 
immunity to the parasite 1-5. In humans this specific acquired 
immunity develops gradually over several years 6, 7, and 
results of  one study seem to suggest that treatment with 
praziquantel speeds up the development of  schistosome-
specific acquired immunity 8. Praziquantel or oxamniquine 
treatment of  schistosome-infected people alters parasite 
specific cellular and humoral responses particularly in 
children (8-10). These treatment-induced changes have been 
associated with resistance to re-infection 11-14. The main 
cytokines which mark each subset are IL-4 and IFN-γ and 
these have a reciprocal cross-inhibitory effect. The relative 
importance of  these functionally distinct T cell subsets and 
their contribution to protective immunity has yet to be fully 
established for the different schistosomes affecting humans 
during acute infection and post treatment. However, from 
recent reports, protection (against schistosome infection??) 
has been associated with Th2 responses, while Th1 responses 
cannot be related to susceptibility but a developmental stage 
after exposure 15-17. A range of  cytokines are now documented 
to be produced by the effector T helper cells. Furthermore, 
observations that the regulatory arm of  the immune system 
develops with sustained exposure to schistosomes and 
their products suggest that they are likely to play a role 
during the establishment and maintenance of  the infected 
condition. This re-infection study showed the cytokine 
profiles that appear before treatment and the change in 
the period following treatment with either praziquantel or 
oxamniquine. The knowledge thus gained should be helpful 
in understanding how the immune response is modulated 
during infection with S.mansoni and following treatment with 
either praziquantel or oxamniquine. Recently we showed that 
ratios of  IL-4:IFN-γ increased in S. haematobium-infected 
children after treatment with praziquantel 15,16. The study 
also showed a significant increase in cell proliferation after 
treatment. This suggests that treatment-induced immune 
changes are more complicated involving much more than 
just cytokine increases or decreases.16
 
Previous studies have examined factors, which affect the 
changes in immune responses following treatment and 
how they affect re-infection rates 4, 5, 11, 12, 15-19. These studies 
mostly dealt with praziquantel or oxamniquine and not 
many compared the effect of  the commonly used drugs in 
S.mansoni and in mixed schistosome infections. However, to 
date, there have been no studies of  the nature of  treatment-
induced immune changes. Characterisation of  these changes 
is important for a better understanding of  how schistosome-
specific acquired immunity develops and is essential for 
vaccine development and schistosomiasis control. We 
compared the cell-mediated immune changes in Zimbabwean 
subjects treated with two types of  drugs which have different 
modes of  action. Praziquantel acts by interfering with the 
Ca2+ uptake, causing muscle contraction and worm paralysis 
20. This causes tegumental damage and eventually worm 
death. Oxamniquine acts by binding to worm DNA causing 
an irreversible inhibition of  nucleic acid synthesis 20, 21. The 
two drugs were used to determine if  there is any drug related 
differences in the changes in immune responses in treated 
children. 
Methods 
Study Ethical Approval
The Medical Research Council of  Zimbabwe approved the 
study protocol. The Provincial and District Medical Directors 
and the District Health Executive Board gave permission to 
conduct the study. Parents and guardians of  the participants 
agreed that the informed verbal consent obtained was 
sufficient. Treatment was offered to all infected participants 
after initial screening and to all participants at the end of  the 
study.
Study site and sample collection
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The study was conducted between 2002 and 2004 and 
recruited individuals attending school in Chiredzi, South 
Eastern Zimbabwe, where S.haematobium and S. mansoni 
is endemic. A total of   410 school going individuals aged 
between 6 and 18 years  were surveyed after the aims of  the 
study had been explained to them. Only participants infected 
with S. mansoni  were divided into groups based on their sex 
and age before being randomly allocated to one treatment, 
with either praziquantel or oxamniquine. From these 148 
children were selected for inclusion into the cell mediated 
immunity study cohort. The inclusion criteria were that each 
participant was expected to provide two stool samples on 
any of  3 consecutive days for S. mansoni detection, at least 2 
urine samples on three consecutive days for S. haematobium 
detection. Each participant was also expected to   be willing 
to have a blood sample taken for cell-mediated immunity 
assays both before treatment and at 6 and 18 weeks after 
treatment. Fifty-five children (29 male, 26 female) received 
the recommended dose (whats the recommended dose for 
this drug??) of  oxamniquine . Sixty-five children (31 male, 
34 female) received the recommended dose of  praziquantel, 
40mg/kg body weight. Twenty eight children (12 male, 16 
female) who were neither infected with S. mansoni nor 
S. haematobium become the negative controls  for both 
treatments after the screening process. Those absent on 
treatment days were treated at the second field visit, six weeks 
later when parasitology and blood samples were collected as 
before. Three replicate slides were prepared for each stool 
sample and processed following the Kato-Katz procedure 
to detect any S. mansoni eggs while the urine filtration 
method was used to detect any S. haematobium eggs in urine 
samples 22, 23. At the same time a blood sample was collected 
for cellular assays, the cells were processed and preserved in 
liquid nitrogen according to methods by Hviid et al., (24). 
Observations on cellular immune responses were made on 
PBMC, which were collected pre-treatment, 6 and 18 weeks 
post treatment after stimulation with S. mansoni worm and 
egg antigens and PHA, observing possible proliferation and 
the profiles of  cytokine production over 5 days incubation 
period . 
PBMC proliferation assays
On the day of  analysis, the cryopreserved PBMC were rapidly 
transferred asceptically into 10 ml washing media (RPMI 
1640). The cells were washed by centrifugation at 250g for 
10 minutes to remove the DMSO and resuspended in 10 ml 
of  complete media containing RPMI 1640, gentamycin, 10 
% AB serum, HEPES, non essential amino acids and sodium 
pyruvate. Cells were enumerated and viability determined 
using tryphan blue (0.2 % w/v) stain before incubation. Cells 
were cultured in a ml of  medium in a 24 well tissue culture 
plates. The cells from each individual had unstimulated 
cells as a negative control and cells stimulated with 10 μg/
ml phytohaemaglutinin (PHA) as positive control. Crude 
S. mansoni antigens SEA and SWAP were used to study 
specific stimulation of  the cells at 15μg/ml. The plates were 
incubated in a 5 % CO2 humidified incubator at 37°C for 5 
days. The cells were harvested, while cell free supernatants 
were collected and stored at –70 °C before assaying for 
cytokines.  After harvesting the supernatants, the cells were 
instantly harvested and used to enumerate the cell numbers 
from the resuspended cell pellet in 1 ml of  RPMI 1640. 
The method of  determining cell proliferation is comparable 
to the other proliferation assays25 using calorimetric or 
radioactive incorporation. Cell enumeration method avoided 
further incubation after supernatant collection. The resulting 
proliferation was expressed as stimulation index as follows: 
Stimulation Index (SI) = Difference of  mean antigen/
mitogen cell count (post- minus pre-culture) divided by 
difference of  mean control cell culture (post- minus pre-
culture).
Cytokine detection 
Cytokine detection of  IL-4, IL-5, IL-10 and IFN-γ was 
performed on the supernatants harvested from the PBMC 
stimulation after 5 days of  incubation 15-17.  Samples were 
thawed and all 4 cytokines assayed at the same time for 
each sample. IFN-γ, IL-4, IL-5, IL10 cytokine assays were 
conducted using capture ELISAs with antibody sets from 
R&D following previously published protocols 16,17. All 
assays were conducted in duplicate. Absorbance was read at 
405 nm with 630 nm as reference wavelength on a DIAS 
Multiscan reader (Dynatech Laboratories). The absorbance 
minus background levels was interpolated from a standard 
curve to obtain cytokine concentrations in pg/ml (within 15 
pg/ml - 2000 pg/ml range) taking into account the dilution 
factor of  the culture supernatants.
Statistical Analyses
All statistical analyses were performed using the statistical 
package SPSS (SPSS, Chicago). Comparison is made of  
the 2 groups initially infected then treated with the group 
initially uninfected and untreated throughout the study time 
points. To determine if  there were significant differences 
between treatment groups at each time point (treated with 
oxamniquine or praziquantel) Mann-Whitney Test was 
performed. Kruskall Wallis comparison was performed 
between untreated, treated with oxamniquine or praziquantel 
at each follow-up time point. All p values were checked using 
a sequential Bonferoni procedure and were only reported as 
significant if  they satisfied the procedure.
Results
Parasitology
All treated children were confirmed egg negative for both 
S. mansoni and S. haematobium at 6 weeks examination. 
Schistosomiasis infection prevalence among the screened 
school-going participants was 83.2% (341), before treatment 
with either praziquantel or oxamniquine.  For S. mansoni the 
prevalence was 67.9% (278) with arithmetic mean infection 
of  68 epg (please write epg in full the first time you introduce 
it) (95% CI, 26.1-163.9) whilst S.haematobium the prevalence 
was 65.6% (269) with arithmetic mean infection of  56.6 ep 
(shouldn’t this be epg too??) 10ml (95% CI, 16.8- 103.6) of  
urine. After treatment, the prevalence of  schistosomiasis in 
untreated children was 33.3% and 33% after 6 weeks and 
18 weeks, respectively. For S. mansoni the prevalence were 
22% and 24.5%, respectively, whilst for S.haematobium 
it was 22.3% and 18.3%. Pre-treatment infection intensity 
was positively correlated with age but the correlation was 
not statistically significant. Mean infection intensity of  the 
study cohort across the age groups is shown in Figure 1. The 
cohort was equally distributed to the 2 treatment groups, 
while the uninfected were used as control for each of  the 
treatment group.
Cellular proliferations
The general proliferation showed that prior to treatment the 
reactivities are low toward the worm antigen (26.24 ± 4.6 and 
cellular responses after treatment   178
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65.63± 9.3 for praziquantel; 22.95±2.32 and 59.20 ± 7.38 
for oxamniquine), at baseline and 6 weeks post treatment, 
respectively, whilst high toward the egg antigen (Figure 2a & 
2b). However, post treatment with either drug, the immune 
responses toward the worm is elevated whilst that toward 
the egg antigen remained high compared to the uninfected 
and untreated group in each treatment group (Figure 2a & 
2b). The general trend in proliferation was an increase in 
the responses towards the worm antigen post treatment and 
also slightly elevated proliferation toward the eggs antigen in 
infected and treated between 6 and 18 weeks post treatment 
time points.
Cytokine profiles
Cytokine production after S.mansoni antigen stimulation 
was low before treatment in both infected and uninfected 
groups. However, after treatment the initially infected and 
treated produced high levels of  both IL-4 and IL-5 compared 
to IFN-γ (Figure 3a & b and 4a & b). On changes of  IFN-γ 
cytokine trends, response to egg antigens was insignificant 
for both pre- and post-treatment times (χ2 = 5.121;  df  = 
2;  p = 0.077) while for worm antigen stimulation there was 
a significant change in IFN-γ  showing a decreasing trend 
with time (χ2 = 7.366; df  = 2; p = 0.025). There was no 
significant change in other cytokines as compared between 
treatment groups using Mann-Whitney test; while there was 
a general increasing trend pre- and post-treatment (baseline 
and 18 weeks: U=365.0; z = -2.677; p=0.007 and U= 410.5; 
z = -2.154; p=0.031) for IL-4 and IL-5, respectively.  The 
general trend in cytokine profiles was similar for both drugs, 
praziquantel and oxamniquine treatment using IL-10: IFN-γ 
ratios (Figure 5). Using Spearman’s correlations for post-
treatment time points for the different cytokines; a strong 
correlation was observed between the drugs at p<0.01 level; 
for IL-4 (n = 116; rho = 0.711); for IL-5 (n = 115; rho = 
0.625); IL-10 (n=116; rho=0.733) and for IFN-γ  (n=113; 
rho=0.697).
Discussion
It is now widely accepted that treating schistosome-infected 
individuals alters the schistosome-specific cellular (4-6, 9-12, 
26-31) and humoral immune responses (5-6). We reported 
that treatment accelerated the development of  acquired 
humoral immunity in S. haematobium-infected children (9). 
The changes are due to increased antigen presented to the 
immune system following treatment. Treatment with anti-
helminthic drugs kills adult schistosomes. Praziquantel acts 
quickly and kills worms by inducing worm paralysis (20), 
while oxamniquine acts more slowly, binding to the worm 
DNA and RNA stopping protein synthesis (21). Treatment 
induced death of  worms results in an introduction of  
antigens not normally available to the immune system (20, 
21, 29, 32), considering the immune evasion mechanisms of  
the schistosomes. The overall increase in proliferation and in 
levels of  cytokines are likely to be responding to this antigen 
increase (30,31). Such increases in antibody and proliferation 
levels have been reported from studies of  S. mansoni, S. 
haematobium and S. japonicum infected children of  similar 
age groups (29, 32-36). Also increases in proliferation and 
cytokine production post treatment with praziquantel have 
been reported before (15, 16), but to our knowledge to date, 
no study has looked at the effect of  both drugs on the cell-
mediated immune system at the same time. 
 Participants in this study had the highest infection 
intensities, which are attributable to cumulative infection 
and the development of  indices of  protective immunity. In 
schistosomiasis, it has been reported that there is a correlation 
between age and infection intensity 29, 32-36. Therefore, it is not 
surprising that there is a low IFN-γ production compared 
to other cytokines at baseline as immune responses are 
mounted in response to infection, especially IFN-γ which 
is pro-inflammatory and is known to be involved the initial 
immune response against schistosome rinfection 15, 16. As 
infection is eliminated by treatment with either praziquantel 
or oxamniquine, regardless of  both drugs having different 
acting mechanism, antigens become available to the system 
and this contributes to cytokine production. In turn the 
resulting cytokine increase leads to increased immune cells 
proliferation resulting in an even higher level of  cytokine 
production resulting in a better control of  the parasites. This 
pattern was more apparent in response to worm antigens 
compared to the response to egg antigens. It is therefore 
not surprising that pre-treatment proliferation and cytokine 
levels of  children in both drug groups are low for the worm 
antigen that is believed to have immune evasion mechanism 
while post treatment the drugs would kill the worms and 
make the antigens available and become recognised by the 
immune response. The response towards the egg antigens 
remained elevated but not significantly changed throughout 
the study, indicating that these antigens maybe in constant 
recognition by the immune cells, as the eggs stimulate the 
immune responses during each laying process. Such intense 
cytokine response to eggs is likely to occur in cases where 
there is granuloma formation and liver fibrosis.
The individuals in the area had high infection intensities, 
and on testing PBMC samples for proliferative responses 
to schistosome-specific stimulation, infected individuals, 
showed higher responses before treatment compared 
to uninfected individuals, suggesting the possibility of  
the individuals trying to establish an acquired protective 
immunity that normally develops with age after second 
decade of  life (1-6). The infected participants showed an 
immunomodulation of  their responses resulting in cellular 
unresponsiveness that has been reported before. This seems 
to occur when infections are intense and as the parasite 
and the host defences establish an apparent equilibrium 
enabling continued coexistence. Infected participants from 
the area were found to have lower proliferative responses 
to both worm and egg antigen stimulation before treatment 
as compared to post treatment. A possible interpretation 
of  these data is that antigens became available for immune 
recognition after treatment, and thus treatment may have 
promoted the development of  a protective immune response 
χ. At 6 and 18 weeks after treatment, there was a general 
increase in proliferative responses in the infected group. The 
PBMCs from participants treated with either praziquantel or 
oxamniquine showed similar patterns of  proliferation and 
production of  cytokines when compared with the uninfected 
and untreated participants in the area who, in turn had very 
low levels of  proliferation and cytokine production. These 
data may seem to suggest that infected subjects in the area 
might have been at different stages of  acute infection but still 
depicted a similar immune response in which the deleterious 
effects of  cellular proliferation is modulated, probably by 
the effects of  IL-4 and IL10 which are considered as anti-
inflammatory 38, 39. Such an interpretation is consistent 
with the age/prevalence and age/intensity data from 
different transmission areas. However, treatment with either 
praziquantel or oxamniquine revealed similar effects on the 
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immune response.
Both praziquantel and oxamniquine caused the modulation 
of  immune responses, a similar cytokine pattern to that 
shown for oxamniquine of  the raised IFN-γ in those 
who were infected, during all the examination times, post 
treatment 40-42. In the same individuals before treatment, 
raised levels of  IL-4 and IL-5 were also observed, which is 
consistent with the dominance of  IL-4, IL-5 later in chronic 
infections and a controlling role of  IL-10 as reported by other 
investigators in S.japonicum 40. The data are indicative of  the 
counter-balancing of  IL-4 and IFN-γ, opposing or down 
regulating each other’s effects, especially before treatment 
was administered. IL-4, IL-5 and IL-10 were markedly 
raised in infected and treated children after treatment. Some 
investigators 27 have reported similar results of  restored and 
increased IL-4 levels post treatment from S.haematobium 
infected patients, while another study (28) which worked 
on S.mansoni infected patients showed elevated levels of  
IL-5 in those who were said to be resistant to infection. 
Similar effects wer shown in the post treatment scenario. It 
is reasonable to suggest therefore that these raised levels of  
IL-4, IL-5 and IL-10 indicate that both drugs had some kind 
of  an immunising effect modulating the immune system. 
The PBMCs produced a mixture of  cytokines suggesting 
that both Th1 and Th2 cell phenotypes were involved 
during infection. All the subjects produced a pattern of  
Th2-like cytokine response post treatment with either drug. 
The infected subjects showed the balance tipping towards 
the Th1-like response before treatment that could have 
contributed to the individuals with the Th1-like cytokine 
phenotype being either susceptible to or succumbing to the 
infection.
Although it has been proposed that predominant levels of  
IFN-γ may be associated with susceptibility to schistosome 
infection, the findings of  this study seem to suggest 
that IFN-γ may be involved in some early stages of  the 
immune response to schistosome infection 15, 16. IFN-γ is 
generally involved in delayed-type hypersensitivity reactions 
dominating in individuals having acute infections. During 
this period, the immune response is involved in antigen 
processing and mobilisation of  cell-mediated immune 
system in which IFN-γ plays a key regulatory role 40, 41. The 
Th1-like cytokine phenotype observed in this study cannot 
be considered as inducing susceptibility to schistosome 
infection but may possibly indicate a regulatory role of  Th1-
like cytokines in the early responses to infection 40. However, 
in this present study, it was observed that when a Th1-like 
phenotype dominates, the individuals were infected. Perhaps 
due to lack of  the effectors which mediate protection and 
are marked by a Th2-like phenotype. IL-4 and IL-5 which 
mark the Th2-like response are known to stimulate B cells 
to selectively mature and proliferate for production of  a 
particular antibody isotypes, which could ultimately be 
involved in ADCC reactions resulting in multicellular parasite 
killing and preventing any further invasion. The Th1 cytokine 
IFN-γ was found to exist during infection but the cytokine 
persisted at lower levels in treated individuals indicative of  
a dynamic balance which probably begins with increased 
levels of  IFN-γ, a Th1 cytokine; and Th2-like responses 
dominating later in response to infection (15), with this shift 
in response phenotype being enhanced by both praziquantel 
and oxamniquine treatment 41. 
 As reported in several studies and reviews for both 
S.mansoni and S.haematobium infections, Th2-like 
responses are considered protective and the data presented 
in this study shows that this aspect of  an immune response 
can be accelerated by using anti-schistosomes. Infection 
with S. mansoni in individuals in their early second decade 
may exist in an acute phase such that levels of  proliferation 
to schistosome-specific antigen stimulation remain raised 
(references). These data may be helpful in future vaccine 
programmes administered to individuals living in different 
mixed schistosome transmission areas and with co-
distribution of  schistosome drugs. 
The study showed major similarity in both cell proliferation 
and cytokine production before and after treatment in 
participants treated with either of  the two drugs. This 
result suggests that the development of  acquired immunity 
to schistosomes is related more to the antigens they have 
been exposed to rather than any other age-related process, 
which would not be altered by treatment. Two age-related 
factors have been suggested to affect immune responses in 
children the first one being hormonal changes at puberty 
and the second being age-related maturity of  the immune 
system (34-37, 43). If  the latter was the case, and children 
were unable to mount some of  the immune responses due 
to inability to recognize some of  the epitopes, for instance, 
then administered treatment would not have altered their 
ability to mount the observed immune responses. 
The results suggest that before treatment the infected 
individuals had been exposed to adequate antigens to mount 
immune responses to some tegumental or sub-tegumental 
and internal antigens so that treatment only augments the 
response slightly. However, the uninfected individuals had 
barely been exposed to such antigens so that treatment 
greatly increased the levels of  these antigens available to 
the immune system. Work on vaccine candidates against 
schistosome infection has suggested that antigens mostly 
associated with resistance to infection are located within or 
beneath the worm tegument, thereby making it difficult for 
the immune system to access them in live worms 44. Since 
worms have a long life span (3 -7 years) 45, it may take several 
years for the antigens to be released in sufficient amounts for 
immune responses to be mounted and modulated.  
Conclusion
This study provides the first indication of  a relationship 
between treatment-induced cellular changes and pre-treatment 
cytokine levels as well as an alteration of  cytokine profile 
following treatment with commonly used anti-schistosome 
drugs. The results show the relationships between treatment-
induced changes in levels of  IL-4, IL-5, IL-10 and IFN-γ 
related to the level of  acquired immunity before treatment, 
and that the relationship between the Th1 and Th2 cytokine 
levels can be altered by treatment. The level of  acquired 
immunity before treatment is related to experience of  
parasite antigens, this support the hypothesis that acquired 
immunity to schistosomiasis develops as a function of  
experience of  parasitic antigens and that treatment speeds 
up the development of  acquired immunity to tegumental or 
sub-tegumental and internal antigens. Both anti-schistosome 
drugs, praziquantel and oxamniquine, show similar effect on 
the host immune responses at least up to three months post 
treatment. This could be important when applying vaccines 
to population living in endemic areas where both drugs may 
be of  use.
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